← All trials
NCT05463679
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 31, 2024
- Primary completion
- Jun 30, 2025
- Completion date
- Mar 31, 2027
- First posted
- Jul 19, 2022
- Last posted
- Oct 14, 2022
- Enrollment
- 260
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- AYTU BioScienceLead sponsor
- ParexelCollaborator
- Baylor UniversityOverall official - principal investigator
- University of WashingtonOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.